Metric Finance
LearnFAQ
LearnFAQ

Learn / RPRX

NASDAQ: RPRX

Royalty Pharma plc (RPRX) stock, explained like you're 5

Royalty Pharma plc trades on the Nasdaq under the ticker RPRX. It is a large cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 32.7 billion dollars.

Ticker
RPRX
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Large cap, about 32.7 billion dollars

Is Royalty Pharma plc a small, medium or large cap company?

Yes. Royalty Pharma plc is a large cap stock. Its market cap, which is the total value of all its shares, is about 32.7 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Royalty Pharma plc makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves RPRX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Royalty Pharma plc (RPRX) stock price, news, quote and history (Yahoo Finance Singapore)
  • Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. (Stock Titan)
  • Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% Here's Why (MarketBeat)
  • If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today (Benzinga)
  • Royalty Pharma Announces Fourth Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share (Quiver Quantitative)

Follow RPRX in your daily brief

Each trading day at 5 PM ET we post what happened to Royalty Pharma plc and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow RPRX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Royalty Pharma plc stock

What does Royalty Pharma plc do?

Royalty Pharma plc trades on the Nasdaq under the ticker RPRX. It is a large cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 32.7 billion dollars.

What is the ticker symbol for Royalty Pharma plc?

Royalty Pharma plc trades under the ticker RPRX on the Nasdaq.

What is Royalty Pharma plc's market cap?

Royalty Pharma plc is a large cap stock with a market cap of about 32.7 billion dollars.

How does Royalty Pharma plc make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves RPRX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow RPRX stock every day?

Add RPRX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow RPRX daily

A free brief on Royalty Pharma plc and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare RPRX: RPRX vs NVS, RPRX vs AZN, RPRX vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed